Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Head and Neck Cancer

  Free Subscription


Articles published in Clin Cancer Res

Retrieve available abstracts of 45 articles:
HTML format
Text format



Single Articles


    September 2017
  1. BIKTASOVA AK, Hajek M, Sewell AB, Gary CS, et al
    Demethylation therapy as a targeted treatment for human papilloma virus-associated head and neck cancer.
    Clin Cancer Res. 2017 Sep 15. pii: clincanres.1438.2017.
    PubMed     Text format     Abstract available


    July 2017
  2. WHITESIDE TL
    Head and Neck Carcinoma Immunotherapy: Facts and Hopes.
    Clin Cancer Res. 2017 Jul 27. pii: clincanres.1261.2017.
    PubMed     Text format     Abstract available


  3. MELL LK, Brumund KT, Daniels GA, Advani SJ, et al
    PHASE I TRIAL OF INTRAVENOUS ONCOLYTIC VACCINIA VIRUS (GL-ONC1) WITH CISPLATIN AND RADIOTHERAPY IN PATIENTS WITH LOCOREGIONALLY ADVANCED HEAD AND NECK CARCINOMA.
    Clin Cancer Res. 2017 Jul 5. pii: clincanres.3232.2016.
    PubMed     Text format     Abstract available


    June 2017
  4. LU G, Little JV, Wang X, Zhang H, et al
    Detection of Head and Neck Cancer in Surgical Specimens Using Quantitative Hyperspectral Imaging.
    Clin Cancer Res. 2017 Jun 13. pii: clincanres.0906.2017.
    PubMed     Text format     Abstract available


    May 2017
  5. OZAWA H, Ranaweera R, Izumchenko E, Makarev E, et al
    SMAD4 loss is associated with cetuximab resistance and induction of MAPK/JNK activation in head and neck cancer cells.
    Clin Cancer Res. 2017 May 18. pii: clincanres.1686.2016.
    PubMed     Text format     Abstract available


  6. SKINNER HD, Giri U, Yang LP, Kumar M, et al
    Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer.
    Clin Cancer Res. 2017 May 5. doi: 10.1158/1078-0432.CCR-16-2586.
    PubMed     Text format     Abstract available


    April 2017
  7. ROSENTHAL E, Moore L, Tipirneni K, de Boer E, et al
    Sensitivity and Specificity of Cetuximab-IRDye800CW to Identify Regional Metastatic Disease in Head and Neck Cancer.
    Clin Cancer Res. 2017 Apr 26. pii: clincanres.2968.2016.
    PubMed     Text format     Abstract available


  8. SALOURA V, Fatima A, Zewde M, Kiyotani K, et al
    Characterization of the tumor T-cell receptor repertoire and immune microenvironment in patients with locoregionally advanced squamous cell carcinoma of the head and neck.
    Clin Cancer Res. 2017 Apr 25. pii: clincanres.0103.2017.
    PubMed     Text format     Abstract available


  9. LUDWIG S, Floros T, Theodoraki MN, Hong CS, et al
    Suppression of lymphocyte functions by plasma exosomes correlates with disease activity in patients with head and neck cancer.
    Clin Cancer Res. 2017 Apr 11. pii: clincanres.2819.2016.
    PubMed     Text format     Abstract available


    March 2017
  10. ZHANG S, Zhang B, Tian J, Dong D, et al
    Radiomics features of Multiparametric MRI as Novel Prognostic Factors in Advanced Nasopharyngeal Carcinoma.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2910.2016.
    PubMed     Text format     Abstract available


    February 2017
  11. HSU DS, Hwang WL, Yuh CH, Chu CH, et al
    Lymphotoxin-beta interacts with methylated EGFR to mediate acquired resistance to cetuximab in head and neck cancer.
    Clin Cancer Res. 2017 Feb 14. pii: clincanres.1955.2016.
    PubMed     Text format     Abstract available


    December 2016
  12. BRAND TM, Hartmann S, Bhola NE, Peyser ND, et al
    Human papillomavirus regulates HER3 expression in head and neck cancer: implications for targeted HER3 therapy in HPV(+) patients.
    Clin Cancer Res. 2016 Dec 16. pii: clincanres.2203.2016.
    PubMed     Text format     Abstract available


  13. MUHAMMAD N, Bhattacharya S, Steele R, Phillips NJ, et al
    Involvement of c-Fos in the promotion of cancer stem-like cell properties in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Dec 13. pii: clincanres.2811.2016.
    PubMed     Text format     Abstract available


    October 2016
  14. KERK S, Finkel K, Pearson AT, Warner K, et al
    5T4-targeted therapy ablates cancer stem cells and prevents recurrence of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Oct 25. pii: clincanres.1834.2016.
    PubMed     Text format     Abstract available


  15. YAMAMURA K, Baba Y, Nakagawa S, Mima K, et al
    Human Microbiome Fusobacterium Nucleatum in Esophageal Cancer Tissue Is Associated with Prognosis.
    Clin Cancer Res. 2016.
    PubMed     Text format     Abstract available


    September 2016
  16. MANCIKOVA V, Montero-Conde C, Perales-Paton J, Fernandez AF, et al
    Multilayer OMIC data in medullary thyroid carcinoma identifies the STAT3 pathway as a potential therapeutic target in RETM918T tumors.
    Clin Cancer Res. 2016 Sep 12. pii: clincanres.0947.2016.
    PubMed     Text format     Abstract available


    August 2016
  17. SRIVASTAVA RM, Trivedi S, Concha-Benavente F, Gibson SP, et al
    CD137 stimulation enhances cetuximab induced natural killer (NK): dendritic cell (DC) priming of anti-tumor T cell immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 Aug 5. pii: clincanres.0879.2016.
    PubMed     Text format     Abstract available


    July 2016
  18. ZHANG JX, Chen ZH, Xu Y, Chen JW, et al
    Downregulation of MicroRNA-644a Promotes Esophageal Squamous Cell Carcinoma Aggressiveness and Stem-cell-like Phenotype via Dysregulation of PITX2.
    Clin Cancer Res. 2016 Jul 12. pii: clincanres.0414.2016.
    PubMed     Text format     Abstract available


  19. HARTMANN S, Bhola NE, Grandis JR
    HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment.
    Clin Cancer Res. 2016 Jul 1. pii: clincanres.0951.2016.
    PubMed     Text format     Abstract available


    June 2016

  20. Correction: Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients.
    Clin Cancer Res. 2016;22:3118.
    PubMed     Text format    


    May 2016
  21. TRIVEDI S, Srivastava RM, Concha-Benavente F, Ferrone S, et al
    Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor cellular immunity in head and neck cancer patients.
    Clin Cancer Res. 2016 May 23. pii: clincanres.2971.2015.
    PubMed     Text format     Abstract available


    April 2016
  22. CHAU NG, Hammerman PS
    Heads Up! Predictive Gene Signatures in Head and Neck Cancer May Be Coming Soon.
    Clin Cancer Res. 2016 Apr 29. pii: clincanres.0582.2016.
    PubMed     Text format     Abstract available


  23. ZHANG Y, Koneva LA, Virani S, Arthur AE, et al
    Subtypes of HPV-positive head and neck cancers are associated with HPV characteristics, copy number alterations, PIK3CA mutation, and pathway signatures.
    Clin Cancer Res. 2016 Apr 18. pii: clincanres.0323.2016.
    PubMed     Text format     Abstract available


  24. ZUMSTEG ZS, Morse N, Krigsfeld G, Gupta G, et al
    Taselisib (GDC-0032), a Potent beta-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
    Clin Cancer Res. 2016;22:2009-19.
    PubMed     Text format     Abstract available


  25. SKINNER HD, Giri U, Yang L, Woo SH, et al
    Proteomic profiling identifies PTK2/FAK as a driver of radioresistance in HPV negative head and neck cancer.
    Clin Cancer Res. 2016 Apr 1. pii: clincanres.2785.2015.
    PubMed     Text format     Abstract available


  26. GRANDIS J
    HER2 and HER3 in HPV+ and HPV- HNSCC--Response.
    Clin Cancer Res. 2016;22:1826.
    PubMed     Text format    


  27. MACHIELS JP, Galot R, Schmitz S
    HER2 and HER3 in HPV+ and HPV- HNSCC--Letter.
    Clin Cancer Res. 2016;22:1825.
    PubMed     Text format    


    March 2016
  28. CHEN P, Hu T, Liang Y, Li P, et al
    Neddylation Inhibition Activates the Extrinsic Apoptosis Pathway through ATF4-CHOP-DR5 Axis in Human Esophageal Cancer Cells.
    Clin Cancer Res. 2016 Mar 16. pii: clincanres.2254.2015.
    PubMed     Text format     Abstract available


  29. KOOLE K, Brunen D, van Kempen PM, Noorlag R, et al
    FGFR1 is a potential prognostic biomarker and therapeutic target in head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Mar 2. pii: clincanres.1874.2015.
    PubMed     Text format     Abstract available


    February 2016
  30. COGHILL AE, Bu W, Nguyen H, Hsu WL, et al
    High levels of antibody that neutralize B-cell infection of Epstein-Barr virus and that bind EBV gp350 are associated with a lower risk of nasopharyngeal carcinoma.
    Clin Cancer Res. 2016 Feb 26. pii: clincanres.2299.2015.
    PubMed     Text format     Abstract available


  31. LEE Y, Shin JH, Longmire M, Wang H, et al
    CD44+ cells in head and neck squamous cell carcinoma suppress T cell-mediated immunity by selective constitutive and inducible expression of PD-L1.
    Clin Cancer Res. 2016 Feb 10. pii: clincanres.2665.2015.
    PubMed     Text format     Abstract available


  32. MITANI Y, Liu B, Rao PH, Borra VJ, et al
    Novel MYBL1 Gene Rearrangements with Recurrent MYBL1-NFIB Fusions in Salivary Adenoid Cystic Carcinomas Lacking t(6;9) Translocations.
    Clin Cancer Res. 2016;22:725-33.
    PubMed     Text format     Abstract available


  33. VASSILAKOPOULOU M, Avgeris M, Velcheti V, Kotoula V, et al
    Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Clin Cancer Res. 2016;22:704-13.
    PubMed     Text format     Abstract available


    January 2016
  34. CHAU NG, Li YY, Jo VY, Rabinowits G, et al
    Incorporation of next-generation sequencing into routine clinical care to direct treatment of head and neck squamous cell carcinoma.
    Clin Cancer Res. 2016 Jan 13. pii: clincanres.2314.2015.
    PubMed     Text format     Abstract available


    December 2015
  35. ROTHENBERG SM, Daniels GH, Wirth LJ
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Response.
    Clin Cancer Res. 2015;21:5640-5641.
    PubMed     Text format    


  36. HUILLARD O, Tenenbaum F, Clerc J, Goldwasser F, et al
    Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib-Letter.
    Clin Cancer Res. 2015;21:5639.
    PubMed     Text format    


    November 2015
  37. ROMICK-ROSENDALE LE, Hoskins EE, Privette Vinnedge LM, Foglesong GD, et al
    Defects in the Fanconi anemia pathway in head and neck cancer cells stimulate tumor cell invasion through DNA-PK and Rac1 signaling.
    Clin Cancer Res. 2015 Nov 24. pii: clincanres.2209.2015.
    PubMed     Text format     Abstract available


    October 2015
  38. SWIERNIAK M, Wojcicka A, Czetwertynska M, Dlugosinska J, et al
    Association Between GWAS-derived rs966423 Genetic Variant and Overall Mortality in Patients with Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Oct 21. pii: clincanres.1746.2015.
    PubMed     Text format     Abstract available


    August 2015
  39. NAIR A, Lemery SJ, Yang J, Marathe A, et al
    FDA Approval Summary: Lenvatinib for Progressive, Radio-iodine-Refractory Differentiated Thyroid Cancer.
    Clin Cancer Res. 2015 Aug 31. pii: clincanres.1377.2015.
    PubMed     Text format     Abstract available


  40. SCHLUMBERGER M, Jarzab B, Cabanillas ME, Robinson BG, et al
    A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC).
    Clin Cancer Res. 2015 Aug 26. pii: clincanres.1127.2015.
    PubMed     Text format     Abstract available


    June 2015
  41. CASAK SJ, Fashoyin-Aje I, Lemery SJ, Zhang L, et al
    FDA Approval Summary: Ramucirumab for Gastric Cancer.
    Clin Cancer Res. 2015 Jun 5. pii: clincanres.0600.2015.
    PubMed     Text format     Abstract available


  42. JURIC D, Dienstmann R, Cervantes A, Hidalgo M, et al
    Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors.
    Clin Cancer Res. 2015;21:2462-70.
    PubMed     Text format     Abstract available


    May 2015
  43. MEHTA A, Zhang L, Boufraqech M, Liu-Chittenden Y, et al
    Inhibition of survivin with YM155 induces durable tumor response in anaplastic thyroid cancer.
    Clin Cancer Res. 2015 May 5. pii: clincanres.3251.2014.
    PubMed     Text format     Abstract available


    April 2015
  44. MACDONALD AJ, Johns N, Stephens N, Greig C, et al
    Habitual Myofibrillar Protein Synthesis Is Normal in Patients with Upper GI Cancer Cachexia.
    Clin Cancer Res. 2015;21:1734-40.
    PubMed     Text format     Abstract available


    December 2014
  45. ROTHENBERG SM, McFadden DG, Palmer EL, Daniels GH, et al
    Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
    Clin Cancer Res. 2014 Dec 30. pii: clincanres.2915.2014.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Head and Neck Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: